Emergency use authorisation of Corbevax for 5-12 age group recommended

The expert panel of India's apex drug regulator on Thursday recommended grant of emergency use authorisation to Covid vaccine Corbevax for those in the 5-12 years age bracket

The expert panel of India's apex drug regulator recommended grant of emergency use authorisation to Covid vaccine Corbevax for those in the 5-12 years age bracket.

According to a source familiar with the development, the Subject Expert Committee has recommended Drug Controller General of India grant the emergency use authorisation to Hyderabad-based Biological E's Corbevax for this age. However, the emergency use authorisation may be the subject of certain conditions, the source added.

Earlier in the day, the panel held a meeting to discuss the recommendations on restricted emergency use of Bharat Biotech's Covaxin and Biological E's Corbevax vaccines among children aged 5-12.

The SEC has sent the recommendations to the DCGI. After the DCGI's nod to the recommendation, the Union Health Ministry may give final approval to begin the vaccination for this age group.

Corbevax vaccine is India's first indigenously-developed protein sub-unit vaccine against Covid-19. This vaccine is currently being administered to children in the age group 12-14 years.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!